Protea Biosciences Group Inc (PRGB)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Protea Biosciences Group Inc (PRGB) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011230
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protea Biosciences Group Inc (Protea) is a biotechnology company that develops mass spectometry solutions. The company offers technology for the characterization, identification, and quantitation of biologically-important molecules for research, pharmaceutical development, and diagnostic applications. Its products include protein sample preparation, functionalized pipette tips and plates, gel protein separation and recovery, mass spectrometry standards and amplus HPLC columns. Protea’s services include mass spec imaging services and bioanalytical services. The company’s bioanalytical services include biotherapeutic characterization, biomarker discovery, advanced proteomics and protein and peptide quantitation, among others. It also provides label free imaging, translational, and drug and metabolite distribution. The company serves in the fields of pharmaceutical, clinical, academic and industrial research. Protea is headquartered in Morgantown, West Virginia, the US.

Protea Biosciences Group Inc (PRGB) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Protea Biosciences Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Protea Biosciences Group Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Protea Biosciences Group Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Protea Biosciences Group Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Protea Biosciences Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Protea Biosciences Group Inc, Medical Equipment, Deal Details 12
Venture Financing 12
Protea Biosciences Raises US$0.28 Million In Venture Financing 12
Protea Biosciences Secures US$1.05 Million In Venture Financing 13
Partnerships 14
Protea Biosciences Enters into Licensing Agreement with Yale University 14
Protea Biosciences Enters into Research Agreement with Vaccine and Immunotherapy Center 15
Protea Biosciences Enters into Agreement with Massachusetts General Hospital 16
Protea Biosciences Extends Partnership with Protein Metrics 17
Protea Biosciences Enters into Agreement with Agilent Technologies 18
Protea Biosciences Enters into Agreement with InSphero for 3D Technologies 19
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 20
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 21
Equity Offering 22
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 22
Protea Biosciences Group Raises USD0.6 Million in Private Placement 23
Protea Biosciences to Raise Funds through Public Offering of Shares 24
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 25
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 26
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 27
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 28
Debt Offering 29
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 29
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 30
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 31
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 32
Asset Transactions 33
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 33
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 34
United States Department of Agriculture Acquires Laesi DP-1000 from Protea Biosciences 35
Acquisition 36
SRKP 5 Acquires Protea Biosciences In Reverse Takeover Transaction 36
Protea Biosciences Group Inc – Key Competitors 37
Protea Biosciences Group Inc – Key Employees 38
Protea Biosciences Group Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Apr 18, 2017: Protea Announces 2016 Year End Results 40
Nov 22, 2016: Protea Announces Third Quarter 2016 Results 41
Aug 16, 2016: Protea Announces Second Quarter 2016 Results 42
May 16, 2016: Protea Announces First Quarter 2016 Results 43
Mar 16, 2016: Protea Announces 2015 Year End Results 44
Corporate Communications 45
Nov 10, 2016: Protea Appoints David Halverson As President 45
Product News 46
Apr 19, 2016: New Potential Lung Cancer Biomarkers Identified 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Protea Biosciences Group Inc, Medical Equipment, Key Facts, 2016 2
Protea Biosciences Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Protea Biosciences Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Protea Biosciences Group Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Protea Biosciences Group Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Protea Biosciences Group Inc, Deals By Market, 2011 to YTD 2017 9
Protea Biosciences Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Protea Biosciences Raises US$0.28 Million In Venture Financing 12
Protea Biosciences Secures US$1.05 Million In Venture Financing 13
Protea Biosciences Enters into Licensing Agreement with Yale University 14
Protea Biosciences Enters into Research Agreement with Vaccine and Immunotherapy Center 15
Protea Biosciences Enters into Agreement with Massachusetts General Hospital 16
Protea Biosciences Extends Partnership with Protein Metrics 17
Protea Biosciences Enters into Agreement with Agilent Technologies 18
Protea Biosciences Enters into Agreement with InSphero for 3D Technologies 19
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 20
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 21
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 22
Protea Biosciences Group Raises USD0.6 Million in Private Placement 23
Protea Biosciences to Raise Funds through Public Offering of Shares 24
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 25
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 26
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 27
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 28
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 29
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 30
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 31
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 32
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 33
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 34
United States Department of Agriculture Acquires Laesi DP-1000 from Protea Biosciences 35
SRKP 5 Acquires Protea Biosciences In Reverse Takeover Transaction 36
Protea Biosciences Group Inc, Key Competitors 37
Protea Biosciences Group Inc, Key Employees 38
Protea Biosciences Group Inc, Subsidiaries 39

★海外企業調査レポート[Protea Biosciences Group Inc (PRGB)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Stobart Group Limited (STOB):企業の財務・戦略的SWOT分析
    Stobart Group Limited (STOB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Tulip Oil Holding BV:石油・ガス:M&Aディール及び事業提携情報
    Summary Tulip Oil Holding BV (Tulip Oil) is an upstream oil and gas development and production company that explores and develops undeveloped oil and gas field discoveries. The company's activities include redeveloping abandoned or mature onshore oil and gas ?elds, developing onshore stranded oil an …
  • The Bank of Nova Scotia:企業のM&A・事業提携・投資動向
    The Bank of Nova Scotia - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Bank of Nova Scotia Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Energy Transfer Partners, L.P.:戦略・SWOT・企業財務分析
    Energy Transfer Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Energy Transfer Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • National Electric Power Co:企業の戦略的SWOT分析
    National Electric Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Centrotec Sustainable AG (CEV):企業の財務・戦略的SWOT分析
    Summary Centrotec Sustainable AG (Centrotec) is an energy company that provides energy saving systems. The company provides products such as medical technology plastics, climate systems, gas flue systems and engineering plastics, among others. It also offers ventilation with heat recovery, heating s …
  • NeuroScientific Biopharmaceuticals Ltd (NSB):企業の財務・戦略的SWOT分析
    NeuroScientific Biopharmaceuticals Ltd (NSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Genisphere LLC-製薬・医療分野:企業M&A・提携分析
    Summary Genisphere LLC (Genisphere) is a nanotechnology company which provides DNA-based targeted drug delivery solutions. The company utilizes its proprietary 3DNA platform which enables the application in gene delivery, biologics, small molecules, and RNAi therapuetics. It develops pipeline produc …
  • Tokyo Gas Co Ltd (9531)-石油・ガス分野:企業M&A・提携分析
    Summary Tokyo Gas Co Ltd (Tokyo Gas) is a gas utility that produces, supplies and markets liquefied natural gas (LNG). It also produces, supplies and sells electricity. Tokyo Gas also has overseas upstream, midstream and downstream businesses. It provides engineering solutions, gas appliances and ga …
  • MannKind Corp (MNKD):製薬・医療:M&Aディール及び事業提携情報
    Summary MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high …
  • Barrett Business Services Inc (BBSI):企業の財務・戦略的SWOT分析
    Summary Barrett Business Services Inc (BBSI) is a management consulting company that offers business management solutions. The company’s services include human capital management, preferred payroll, and staffing. Its payroll services handles deductions, liens, tax levies, tax payments, w-2s, and wag …
  • Central Japan Railway Co (9022):企業の財務・戦略的SWOT分析
    Central Japan Railway Co (9022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • LycoRed Ltd:戦略・SWOT・企業財務分析
    LycoRed Ltd - Strategy, SWOT and Corporate Finance Report Summary LycoRed Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Impax Laboratories Inc (IPXL)-製薬・医療分野:企業M&A・提携分析
    Summary Impax Laboratories Inc (Impax) develops, manufactures and markets generic and branded pharmaceuticals. It offers solid dose and alternative dosage form generic drugs in a broad range of therapeutic areas; and proprietary branded pharmaceutical products for the treatment of central nervous sy …
  • Rafael Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rafael Pharmaceuticals Inc (Rafael Pharmaceuticals), formerly Cornerstone Pharmaceuticals Inc, is a clinical-stage, metabolic oncology therapeutics company, which focuses to develop and commercialize cancer metabolism based drugs. The company’s lead drug candidate CPI-613 is designed to targ …
  • Citius Pharmaceuticals Inc (CTXR):企業の財務・戦略的SWOT分析
    Summary Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care, and critical care drug products. The company’s proprietary product candidates include Min …
  • Archroma Management GmbH:企業の戦略的SWOT分析
    Archroma Management GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • American Superconductor Corp (AMSC):企業の財務・戦略的SWOT分析
    American Superconductor Corp (AMSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • XERIS Pharmaceuticals Inc (XERS):医療機器:M&Aディール及び事業提携情報
    Summary XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of ultra concentr …
  • Deutsche Borse AG:企業の戦略・SWOT・財務情報
    Deutsche Borse AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Borse AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆